Shen, Nicole T Leff, Jared A Schneider, Yecheskel Crawford, Carl V Maw, Anna Bosworth, Brian and Simon, Matthew S 2017. Cost-Effectiveness Analysis of Probiotic Use to Prevent Clostridium difficile Infection in Hospitalized Adults Receiving Antibiotics. Open Forum Infectious Diseases, Vol. 4, Issue. 3,
Scappaticci, Gianni B. Perissinotti, Anthony J. Nagel, Jerod L. Bixby, Dale L. and Marini, Bernard L. 2017. Risk factors and impact of Clostridium difficile recurrence on haematology patients. Journal of Antimicrobial Chemotherapy, Vol. 72, Issue. 5, p. 1488.
Kuntz, Jennifer L. Baker, Jennifer M. Kipnis, Patricia Li, Sherian Xu Liu, Vincent Xie, Yang Marcella, Stephen and Escobar, Gabriel J. 2017. Utilization of Health Services Among Adults With Recurrent Clostridium difficile Infection: A 12-Year Population-Based Study. Infection Control & Hospital Epidemiology, Vol. 38, Issue. 01, p. 45.
Hill, David R. and Spence, Jason R. 2017. Gastrointestinal Organoids: Understanding the Molecular Basis of the Host–Microbe Interface. Cellular and Molecular Gastroenterology and Hepatology, Vol. 3, Issue. 2, p. 138.
Tariq, Raseen Weatherly, Renee M. Kammer, Patricia P. Pardi, Darrell S. and Khanna, Sahil 2017. Experience and Outcomes at a Specialized Clostridium difficile Clinical Practice. Mayo Clinic Proceedings: Innovations, Quality & Outcomes, Vol. 1, Issue. 1, p. 49.
Chen, Becky Avinashi, Vishal and Dobson, Simon 2017. Fecal microbiota transplantation for recurrent Clostridium difficile infection in children. Journal of Infection, Vol. 74, p. S120.
Maghdoori, Sara and Moghadas, Seyed M. 2017. Assessing the effect of patient screening and isolation on curtailing Clostridium difficile infection in hospital settings. BMC Infectious Diseases, Vol. 17, Issue. 1,
Bang, Byoung Wook Park, Jin-Seok Kim, Hyung Kil Shin, Yong Woon Kwon, Kye Sook Kwon, Hea Yoon Baek, Ji Hyeon and Lee, Jin-Soo 2017. Fecal Microbiota Transplantation for Refractory and Recurrent Clostridium difficile Infection: A Case Series of Nine Patients. The Korean Journal of Gastroenterology, Vol. 69, Issue. 4, p. 226.
Reigadas, E. Alcalá, L. Marín, M. Martín, A. and Bouza, E. 2017. Clinical, immunological and microbiological predictors of poor outcome in Clostridium difficile infection. Diagnostic Microbiology and Infectious Disease, Vol. 88, Issue. 4, p. 330.
Vindigni, Stephen M. and Surawicz, Christina M. 2017. Fecal Microbiota Transplantation. Gastroenterology Clinics of North America, Vol. 46, Issue. 1, p. 171.
Gigli, Stefano Seguella, Luisa Pesce, Marcella Bruzzese, Eugenia D’Alessandro, Alessandra Cuomo, Rosario Steardo, Luca Sarnelli, Giovanni and Esposito, Giuseppe 2017. Cannabidiol restores intestinal barrier dysfunction and inhibits the apoptotic process induced by Clostridium difficile toxin A in Caco-2 cells. United European Gastroenterology Journal, p. 205064061769862.
Rodrigues, Rodrigo Barber, Grant E. and Ananthakrishnan, Ashwin N. 2017. A Comprehensive Study of Costs Associated With Recurrent Clostridium difficile Infection. Infection Control & Hospital Epidemiology, Vol. 38, Issue. 02, p. 196.
Curry, Scott R. 2017. Clostridium difficile. Clinics in Laboratory Medicine, Vol. 37, Issue. 2, p. 341.
O’Gorman, Molly A. Michaels, Marian G. Kaplan, Sheldon L. Otley, Anthony Kociolek, Larry K. Hoffenberg, Edward J. Kim, Kwang Sik Nachman, Sharon Pfefferkorn, Marian D. Sentongo, Timothy Sullivan, Janice E. and Sears, Pamela 2017. Safety and Pharmacokinetic Study of Fidaxomicin in Children With Clostridium difficile–Associated Diarrhea: A Phase 2a Multicenter Clinical Trial. Journal of the Pediatric Infectious Diseases Society,
Reigadas, E. Alcalá, L. Valerio, M. Marín, M. Martin, A. and Bouza, E. 2016. Toxin B PCR cycle threshold as a predictor of poor outcome ofClostridium difficileinfection: a derivation and validation cohort study. Journal of Antimicrobial Chemotherapy, Vol. 71, Issue. 5, p. 1380.
Shah, D.N. Aitken, S.L. Barragan, L.F. Bozorgui, S. Goddu, S. Navarro, M.E. Xie, Y. DuPont, H.L. and Garey, K.W. 2016. Economic burden of primary compared with recurrent Clostridium difficile infection in hospitalized patients: a prospective cohort study. Journal of Hospital Infection, Vol. 93, Issue. 3, p. 286.
Sheitoyan-Pesant, Caroline Abou Chakra, Claire Nour Pépin, Jacques Marcil-Héguy, Anaïs Nault, Vincent and Valiquette, Louis 2016. Clinical and Healthcare Burden of Multiple Recurrences ofClostridium difficileInfection. Clinical Infectious Diseases, Vol. 62, Issue. 5, p. 574.
Lee, Christine Louie, Thomas J. Weiss, Karl Valiquette, Louis Gerson, Marvin Arnott, Wendy and Gorbach, Sherwood L. 2016. Fidaxomicin versus Vancomycin in the Treatment ofClostridium difficileInfection: Canadian Outcomes. Canadian Journal of Infectious Diseases and Medical Microbiology, Vol. 2016, p. 1.
Ross, Caná L. Spinler, Jennifer K. and Savidge, Tor C. 2016. Structural and functional changes within the gut microbiota and susceptibility to Clostridium difficile infection. Anaerobe, Vol. 41, p. 37.
Lapointe-Shaw, Lauren Tran, Kim L. Coyte, Peter C. Hancock-Howard, Rebecca L. Powis, Jeff Poutanen, Susan M. Hota, Susy and Deshpande, Abhishek 2016. Cost-Effectiveness Analysis of Six Strategies to Treat Recurrent Clostridium difficile Infection. PLOS ONE, Vol. 11, Issue. 2, p. e0149521.
To describe the epidemiology, diagnosis, risk factors, patient impact, and treatment strategies for recurrent Clostridium difficile-associated disease (CDAD).
Data were collected as part of a blinded, placebo-controlled clinical trial testing a new combination treatment for recurrent CDAD. Retrospective data regarding prior CDAD episodes were collected from interviews and medical-chart review. Prospective data on the current CDAD episode, risk factors, and recurrence rates were collected during a 2-month follow-up.
National referral study.
Patients with recurrent CDAD.
Treatment with a 10-day course of low-dose (500 mg/d) or high-dose (2 g/d) vancomycin or metronidazole (1 g/d).
Recurrent CDAD was found to have a lengthy course involving multiple episodes of diarrhea, abdominal cramping, nausea, and fever. CDAD may recur over several years despite frequent treatment with antibiotics. Recurrence rates were similar regardless of the choice or dose of antibiotic. Recurrent CDAD is not a trivial disease: patients may have multiple episodes (as many as 14), may require hospitalization, and the mean lifetime cost of direct medical care was $10,970 per patient. Fortunately, the disease does not become progressively more severe as the number of episodes increase. Two risk factors predictive for recurrent CDAD were found: increasing age and a decreased quality-of-life score at enrollment.
Recurrent CDAD is a persistent disease that may result in prolonged hospital stays, additional medical costs, and rare serious complications.
Email your librarian or administrator to recommend adding this journal to your organisation's collection.
Full text views reflects the number of PDF downloads, PDFs sent to Google Drive, Dropbox and Kindle and HTML full text views.
* Views captured on Cambridge Core between September 2016 - 16th January 2018. This data will be updated every 24 hours.